Anticipated expansion of a new approach to treating hypertension without medication by catheter-based renal denervation

The RADIANCE-HTN SOLO trial recently revealed that catheter-based renal denervation (RDN) using endovascular ultrasound could reduce the ambulatory blood pressure (ABP) after 2 months without medications in patients who had combined systolic/diastolic hypertension (HT) (1). Accordingly, RDN is being re-evaluated because of the contrast to the disappointing results of the SYMPLICITY HTN-3 trial (2), which indicated that RDN did not have an antihypertensive effect.